Janux Therapeutics, Inc. Depreciation
Janux Therapeutics, Inc. (JANX) reported Depreciation of $932.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- Janux Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $463.00K, a 14.42% decline year-over-year.
- Janux Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $469.00K, a 9.63% decline year-over-year.
- Janux Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $468.00K, a 8.59% decline year-over-year.
- Janux Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $501.00K, a 1.76% decline year-over-year.
- Janux Therapeutics, Inc. depreciation for fiscal 2025 was $2.03M, a 1.50% decline from fiscal 2024.
- Janux Therapeutics, Inc. depreciation for fiscal 2024 was $2.06M, a 5.37% increase from fiscal 2023.
- Janux Therapeutics, Inc. depreciation for fiscal 2023 was $1.96M, a 132.46% increase from fiscal 2022.
- Janux Therapeutics, Inc. depreciation for fiscal 2022 was $841.00K, a 644.25% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $463.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $932.00K 10-Q · filed 2026-08-06 | $1.40M derived: sum of 3 quarters · filed 2026-08-06 | $1.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $469.00K 10-Q · filed 2026-05-07 | $937.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.44M derived: sum of 3 quarters · filed 2026-05-07 | $1.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $468.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $969.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.51M derived: sum of 3 quarters · filed 2026-08-06 | $2.03M 10-K · filed 2026-02-26 |
| 2025-09-30 | $501.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.04M derived: sum of 2 quarters · filed 2026-08-06 | $1.56M 10-Q · filed 2025-11-06 | $2.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $541.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.06M 10-Q · filed 2026-08-06 | $1.57M derived: sum of 3 quarters · filed 2026-08-06 | $2.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $519.00K 10-Q · filed 2026-05-07 | $1.03M derived: sum of 2 quarters · filed 2026-05-07 | $1.54M derived: sum of 3 quarters · filed 2026-05-07 | $2.05M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $512.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.02M derived: sum of 2 quarters · filed 2026-02-26 | $1.53M derived: sum of 3 quarters · filed 2026-02-26 | $2.06M 10-K · filed 2026-02-26 |
| 2024-09-30 | $510.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.02M derived: sum of 2 quarters · filed 2025-11-06 | $1.55M 10-Q · filed 2025-11-06 | $2.08M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $506.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.04M 10-Q · filed 2025-08-07 | $1.57M derived: sum of 3 quarters · filed 2026-02-26 | $2.07M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $532.00K 10-Q · filed 2025-05-08 | $1.06M derived: sum of 2 quarters · filed 2026-02-26 | $1.56M derived: sum of 3 quarters · filed 2026-02-26 | $2.03M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $531.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.03M derived: sum of 2 quarters · filed 2026-02-26 | $1.50M derived: sum of 3 quarters · filed 2026-02-26 | $1.96M 10-K · filed 2026-02-26 |
| 2023-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $971.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.42M 10-Q · filed 2024-11-06 | $1.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $471.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $924.00K 10-Q · filed 2024-08-07 | $1.33M derived: sum of 3 quarters · filed 2025-02-27 | $1.58M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $453.00K 10-Q · filed 2024-05-08 | $856.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.10M derived: sum of 3 quarters · filed 2025-02-27 | $1.21M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $403.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $652.00K derived: sum of 2 quarters · filed 2025-02-27 | $760.00K derived: sum of 3 quarters · filed 2025-02-27 | $841.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $357.00K derived: sum of 2 quarters · filed 2023-11-07 | $438.00K 10-Q · filed 2023-11-07 | $502.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $189.00K 10-Q · filed 2023-08-08 | $253.00K derived: sum of 3 quarters · filed 2023-08-08 | $280.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $81.00K 10-Q · filed 2023-05-09 | $145.00K derived: sum of 2 quarters · filed 2023-05-09 | $172.00K derived: sum of 3 quarters · filed 2023-05-09 | $185.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $91.00K derived: sum of 2 quarters · filed 2023-03-10 | $104.00K derived: sum of 3 quarters · filed 2023-03-10 | $113.00K 10-K · filed 2023-03-10 |
| 2021-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $40.00K derived: sum of 2 quarters · filed 2022-11-10 | $49.00K 10-Q · filed 2022-11-10 | $58.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $22.00K 10-Q · filed 2022-08-09 | $31.00K derived: sum of 3 quarters · filed 2022-08-09 | $32.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $9.00K 10-Q · filed 2022-05-10 | $18.00K derived: sum of 2 quarters · filed 2022-05-10 | $19.00K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $10.00K derived: sum of 2 quarters · filed 2022-03-18 | $13.00K 10-K · filed 2022-03-18 | |
| 2020-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $4.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $3.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |